You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDyphylline
Accession NumberDB00651  (APRD00769)
TypeSmall Molecule
GroupsApproved
DescriptionA theophylline derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis. [PubChem]
Structure
Thumb
Synonyms
(+-)-7-(2,3-Dihydroxypropyl)theophylline
(+-)-Diprophylline
(+-)-Dyphylline
(±)-diprophylline
(±)-dyphylline
(1,2-Dihydroxy-3-propyl)thiophyllin
1,3-Dimethyl-7-(2,3-dihydroxypropyl)xanthine
7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine
7-(2,3-Dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione
7-(2,3-Dihydroxypropyl)theophylline
7-(beta,gamma-Dihydroxypropyl)theophylline
7-(β,γ-dihydroxypropyl)theophylline
Dihydroxypropyl theopylin
Diprofilina
Diprophylline
Diprophyllinum
Dyphylline
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Protophylline Elixir 100mgelixir100 mgoralRougier Pharma Division Of Ratiopharm Inc1962-12-311999-09-27Canada
Protophylline Inj 500mg/2mlliquid500 mgintramuscular; intravenousRougier Pharma Division Of Ratiopharm Inc1963-12-311999-09-27Canada
Protophylline Solution 100mgsolution100 mgoralRougier Pharma Division Of Ratiopharm Inc1965-12-311999-09-27Canada
Protophylline Sup 500mg Adultessuppository500 mgrectalRougier Pharma Division Of Ratiopharm Inc1962-12-311999-09-27Canada
Protophylline Tab 200mgtablet200 mgoralRougier Pharma Division Of Ratiopharm Inc1962-12-311999-09-27Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Lufyllintablet200 mg/1oralMeda Pharmaceuticals Inc.1976-08-312016-02-29Us
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CorphyllinNippon Shinyaku
DilorSavage
Brand mixtures
NameLabellerIngredients
Jay-phylJay Mac Pharmaceuticals Llc
SaltsNot Available
Categories
UNII263T0E9RR9
CAS number479-18-5
WeightAverage: 254.2426
Monoisotopic: 254.101504956
Chemical FormulaC10H14N4O4
InChI KeyInChIKey=KSCFJBIXMNOVSH-UHFFFAOYSA-N
InChI
InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3
IUPAC Name
7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione
SMILES
CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alkaloids and derivatives. These are naturally occurring chemical compounds that contain mostly basic nitrogen atoms. This group also includes some related compounds with neutral and even weakly acidic properties. Also some synthetic compounds of similar structure are attributed to alkaloids. In addition to carbon, hydrogen and nitrogen, alkaloids may also contain oxygen, sulfur and more rarely other elements such as chlorine, bromine, and phosphorus.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassNot Available
Sub ClassNot Available
Direct ParentAlkaloids and derivatives
Alternative Parents
Substituents
  • Alkaloid or derivatives
  • Xanthine
  • Purinone
  • 6-oxopurine
  • Purine
  • Imidazopyrimidine
  • Pyrimidone
  • Pyrimidine
  • N-substituted imidazole
  • Heteroaromatic compound
  • Vinylogous amide
  • Imidazole
  • Azole
  • Urea
  • Secondary alcohol
  • Lactam
  • 1,2-diol
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema.
PharmacodynamicsDyphylline, a xanthine derivative, is a bronchodilator used for relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema. Dyphylline is a xanthine derivative with pharmacologic actions similar to theophylline and other members of this class of drugs. Its primary action is that of bronchodilation, but it also exhibits peripheral vasodilatory and other smooth muscle relaxant activity to a lesser degree.
Mechanism of actionThe bronchodilatory action of dyphylline, as with other xanthines, is thought to be mediated through competitive inhibition of phosphodiesterase with a resulting increase in cyclic AMP producing relaxation of bronchial smooth muscle as well as antagonism of adenosine receptors.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding84%
Metabolism

Hepatic

Route of eliminationDyphylline exerts its bronchodilatory effects directly and, unlike the­ophylline, is excreted unchanged by the kidneys without being metabolized by the liver. Approximately 88% of a single oral dose can be recovered from the urine unchanged.
Half life2 hours (range 1.8 - 2.1 hours)
ClearanceNot Available
ToxicityLD50=1954 mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.964
Blood Brain Barrier-0.6357
Caco-2 permeable-0.7332
P-glycoprotein substrateSubstrate0.5999
P-glycoprotein inhibitor INon-inhibitor0.9775
P-glycoprotein inhibitor IINon-inhibitor0.9792
Renal organic cation transporterNon-inhibitor0.9289
CYP450 2C9 substrateNon-substrate0.8343
CYP450 2D6 substrateNon-substrate0.8429
CYP450 3A4 substrateNon-substrate0.5446
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.946
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.978
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9758
Ames testNon AMES toxic0.799
CarcinogenicityNon-carcinogens0.8576
BiodegradationNot ready biodegradable0.6129
Rat acute toxicity1.8401 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9489
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Teva pharmaceuticals usa inc
  • Savage laboratories inc div altana inc
  • Meda pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Syruporal
Tabletoral200 mg/1
Elixiroral100 mg
Liquidintramuscular; intravenous500 mg
Solutionoral100 mg
Suppositoryrectal500 mg
Tabletoral200 mg
Prices
Unit descriptionCostUnit
Afinitor 10 mg tablet247.58USD tablet
Afinitor 5 mg tablet234.75USD tablet
Lufyllin-400 tablet4.62USD tablet
Lufyllin 200 mg tablet3.15USD tablet
Dyphylline gg es tablet0.78USD tablet
Dyphylline gg tablet0.69USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point155-157Jones, J.W. and Maney, P.V.; U.S. Patent 2,575,344; November 20,1951; assigned to the State of Iowa.
water solubility3.33E+005 mg/L (at 25 °C)MERCK INDEX (1996)
logP-1.9Not Available
logS-0.17ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility14.3 mg/mLALOGPS
logP-0.98ALOGPS
logP-1.9ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)13.91ChemAxon
pKa (Strongest Basic)-0.97ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area98.9 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity62.09 m3·mol-1ChemAxon
Polarizability24.65 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Jones, J.W. and Maney, P.V.; U.S. Patent 2,575,344; November 20,1951; assigned to the
State of Iowa.

General ReferencesNot Available
External Links
ATC CodesR03DA51R03DA01R03DB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (65.7 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Dyphylline can be decreased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Dyphylline can be decreased when it is combined with 3,4-Dichloroisocoumarin.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Dyphylline can be decreased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
AcebutololAcebutolol may decrease the bronchodilatory activities of Dyphylline.
AdalimumabThe serum concentration of Dyphylline can be decreased when it is combined with Adalimumab.
AdenosineThe therapeutic efficacy of Adenosine can be decreased when used in combination with Dyphylline.
Albumin-interferon alphaThe metabolism of Dyphylline can be decreased when combined with Albumin-interferon alpha.
AllopurinolThe serum concentration of Dyphylline can be increased when it is combined with Allopurinol.
AlogliptinThe serum concentration of Dyphylline can be decreased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Dyphylline can be decreased when it is combined with Alpha-1-proteinase inhibitor.
AlprazolamThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Dyphylline.
AlprenololAlprenolol may decrease the bronchodilatory activities of Dyphylline.
AmobarbitalThe serum concentration of Dyphylline can be decreased when it is combined with Amobarbital.
AmprenavirThe serum concentration of Dyphylline can be decreased when it is combined with Amprenavir.
Antithrombin III humanThe serum concentration of Dyphylline can be decreased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Dyphylline can be decreased when it is combined with Apixaban.
AprotininThe serum concentration of Dyphylline can be decreased when it is combined with Aprotinin.
ArgatrobanThe serum concentration of Dyphylline can be decreased when it is combined with Argatroban.
AsunaprevirThe serum concentration of Dyphylline can be decreased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Dyphylline can be decreased when it is combined with Atazanavir.
AtenololAtenolol may decrease the bronchodilatory activities of Dyphylline.
BarbitalThe serum concentration of Dyphylline can be decreased when it is combined with Barbital.
BatimastatThe serum concentration of Dyphylline can be decreased when it is combined with Batimastat.
BazedoxifeneThe serum concentration of Dyphylline can be increased when it is combined with Bazedoxifene.
BenazeprilThe serum concentration of Dyphylline can be decreased when it is combined with Benazepril.
BenzamidineThe serum concentration of Dyphylline can be decreased when it is combined with Benzamidine.
BetaxololBetaxolol may decrease the bronchodilatory activities of Dyphylline.
BisoprololBisoprolol may decrease the bronchodilatory activities of Dyphylline.
BivalirudinThe serum concentration of Dyphylline can be decreased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Dyphylline can be decreased when it is combined with Boceprevir.
BopindololBopindolol may decrease the bronchodilatory activities of Dyphylline.
BromazepamThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Dyphylline.
BupranololBupranolol may decrease the bronchodilatory activities of Dyphylline.
CandoxatrilThe serum concentration of Dyphylline can be decreased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Dyphylline can be decreased when it is combined with Captopril.
CarbamazepineThe serum concentration of Dyphylline can be decreased when it is combined with Carbamazepine.
CarbimazoleThe serum concentration of Dyphylline can be increased when it is combined with Carbimazole.
CarteololCarteolol may decrease the bronchodilatory activities of Dyphylline.
CeliprololCeliprolol may decrease the bronchodilatory activities of Dyphylline.
ChlordiazepoxideThe therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Dyphylline.
ChlorotrianiseneThe serum concentration of Dyphylline can be increased when it is combined with Chlorotrianisene.
ChymostatinThe serum concentration of Dyphylline can be decreased when it is combined with Chymostatin.
CilastatinThe serum concentration of Dyphylline can be decreased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Dyphylline can be decreased when it is combined with Cilazapril.
CimetidineThe metabolism of Dyphylline can be decreased when combined with Cimetidine.
ClonazepamThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Dyphylline.
ClorazepateThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Dyphylline.
Conjugated Equine EstrogensThe serum concentration of Dyphylline can be increased when it is combined with Conjugated Equine Estrogens.
Dabigatran etexilateThe serum concentration of Dyphylline can be decreased when it is combined with Dabigatran etexilate.
DarunavirThe serum concentration of Dyphylline can be decreased when it is combined with Darunavir.
DiazepamThe therapeutic efficacy of Diazepam can be decreased when used in combination with Dyphylline.
DienestrolThe serum concentration of Dyphylline can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Dyphylline can be increased when it is combined with Diethylstilbestrol.
DisulfiramThe serum concentration of Dyphylline can be increased when it is combined with Disulfiram.
DoxofyllineThe risk or severity of adverse effects can be increased when Dyphylline is combined with Doxofylline.
EcabetThe serum concentration of Dyphylline can be decreased when it is combined with Ecabet.
EdoxabanThe serum concentration of Dyphylline can be decreased when it is combined with Edoxaban.
ElafinThe serum concentration of Dyphylline can be decreased when it is combined with Elafin.
EnalaprilThe serum concentration of Dyphylline can be decreased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Dyphylline can be decreased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Dyphylline can be decreased when it is combined with Enalkiren.
EsmololEsmolol may decrease the bronchodilatory activities of Dyphylline.
EstazolamThe therapeutic efficacy of Estazolam can be decreased when used in combination with Dyphylline.
EstradiolThe serum concentration of Dyphylline can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Dyphylline can be increased when it is combined with Estriol.
EstroneThe serum concentration of Dyphylline can be increased when it is combined with Estrone.
Ethinyl EstradiolThe serum concentration of Dyphylline can be increased when it is combined with Ethinyl Estradiol.
FebuxostatThe serum concentration of the active metabolites of Dyphylline can be increased when Dyphylline is used in combination with Febuxostat.
FlumazenilThe therapeutic efficacy of Flumazenil can be decreased when used in combination with Dyphylline.
FlunitrazepamThe therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Dyphylline.
FlurazepamThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Dyphylline.
FluvoxamineThe metabolism of Dyphylline can be decreased when combined with Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Dyphylline is combined with Formoterol.
FosinoprilThe serum concentration of Dyphylline can be decreased when it is combined with Fosinopril.
FosphenytoinThe serum concentration of Dyphylline can be decreased when it is combined with Fosphenytoin.
GeldanamycinThe serum concentration of Dyphylline can be decreased when it is combined with Geldanamycin.
GenisteinThe serum concentration of Dyphylline can be increased when it is combined with Genistein.
GM6001The serum concentration of Dyphylline can be decreased when it is combined with GM6001.
HexestrolThe serum concentration of Dyphylline can be increased when it is combined with Hexestrol.
HexobarbitalThe serum concentration of Dyphylline can be decreased when it is combined with Hexobarbital.
HirulogThe serum concentration of Dyphylline can be decreased when it is combined with Hirulog.
IndacaterolThe risk or severity of adverse effects can be increased when Dyphylline is combined with Indacaterol.
IndinavirThe serum concentration of Dyphylline can be decreased when it is combined with Indinavir.
Interferon Alfa-2a, RecombinantThe metabolism of Dyphylline can be decreased when combined with Interferon Alfa-2a, Recombinant.
Interferon Alfa-2b, RecombinantThe metabolism of Dyphylline can be decreased when combined with Interferon Alfa-2b, Recombinant.
Interferon alfa-n1The metabolism of Dyphylline can be decreased when combined with Interferon alfa-n1.
Interferon alfacon-1The metabolism of Dyphylline can be decreased when combined with Interferon alfacon-1.
Interferon beta-1aThe metabolism of Dyphylline can be decreased when combined with Interferon beta-1a.
Interferon beta-1bThe metabolism of Dyphylline can be decreased when combined with Interferon beta-1b.
IsoflurophateThe serum concentration of Dyphylline can be decreased when it is combined with Isoflurophate.
IsoniazidThe serum concentration of Dyphylline can be increased when it is combined with Isoniazid.
IsoprenalineThe serum concentration of Dyphylline can be decreased when it is combined with Isoprenaline.
IxazomibThe serum concentration of Dyphylline can be decreased when it is combined with Ixazomib.
LepirudinThe serum concentration of Dyphylline can be decreased when it is combined with Lepirudin.
LevothyroxineThe metabolism of Dyphylline can be increased when combined with Levothyroxine.
LinagliptinThe serum concentration of Dyphylline can be decreased when it is combined with Linagliptin.
LiothyronineThe metabolism of Dyphylline can be increased when combined with Liothyronine.
LiotrixThe metabolism of Dyphylline can be increased when combined with Liotrix.
LisinoprilThe serum concentration of Dyphylline can be decreased when it is combined with Lisinopril.
LithiumThe serum concentration of Lithium can be decreased when it is combined with Dyphylline.
LopinavirThe serum concentration of Dyphylline can be decreased when it is combined with Lopinavir.
LorazepamThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Dyphylline.
MestranolThe serum concentration of Dyphylline can be increased when it is combined with Mestranol.
MethimazoleThe serum concentration of Dyphylline can be increased when it is combined with Methimazole.
MethohexitalThe serum concentration of Dyphylline can be decreased when it is combined with Methohexital.
MethotrexateThe serum concentration of Dyphylline can be increased when it is combined with Methotrexate.
MethylphenobarbitalThe serum concentration of Dyphylline can be decreased when it is combined with Methylphenobarbital.
MetoprololMetoprolol may decrease the bronchodilatory activities of Dyphylline.
MexiletineThe metabolism of Dyphylline can be decreased when combined with Mexiletine.
MidazolamThe therapeutic efficacy of Midazolam can be decreased when used in combination with Dyphylline.
MoexiprilThe serum concentration of Dyphylline can be decreased when it is combined with Moexipril.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Dyphylline can be decreased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NadololNadolol may decrease the bronchodilatory activities of Dyphylline.
Natural alpha interferonThe metabolism of Dyphylline can be decreased when combined with Natural alpha interferon.
NCX 4016The serum concentration of Dyphylline can be decreased when it is combined with NCX 4016.
NebivololNebivolol may decrease the bronchodilatory activities of Dyphylline.
NelfinavirThe serum concentration of Dyphylline can be decreased when it is combined with Nelfinavir.
NitrazepamThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Dyphylline.
OlodaterolThe risk or severity of adverse effects can be increased when Dyphylline is combined with Olodaterol.
OmapatrilatThe serum concentration of Dyphylline can be decreased when it is combined with Omapatrilat.
OtamixabanThe serum concentration of Dyphylline can be decreased when it is combined with Otamixaban.
OxazepamThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Dyphylline.
OxprenololOxprenolol may decrease the bronchodilatory activities of Dyphylline.
PancuroniumThe risk or severity of adverse effects can be increased when Dyphylline is combined with Pancuronium.
Peginterferon alfa-2aThe metabolism of Dyphylline can be decreased when combined with Peginterferon alfa-2a.
Peginterferon alfa-2bThe metabolism of Dyphylline can be decreased when combined with Peginterferon alfa-2b.
Peginterferon beta-1aThe metabolism of Dyphylline can be decreased when combined with Peginterferon beta-1a.
PenbutololPenbutolol may decrease the bronchodilatory activities of Dyphylline.
PentobarbitalThe serum concentration of Dyphylline can be decreased when it is combined with Pentobarbital.
PentoxifyllineThe serum concentration of Dyphylline can be increased when it is combined with Pentoxifylline.
PerindoprilThe serum concentration of Dyphylline can be decreased when it is combined with Perindopril.
PhenobarbitalThe serum concentration of Dyphylline can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Dyphylline can be decreased when it is combined with Phenytoin.
PhosphoramidonThe serum concentration of Dyphylline can be decreased when it is combined with Phosphoramidon.
PindololPindolol may decrease the bronchodilatory activities of Dyphylline.
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Dyphylline.
Polyestradiol phosphateThe serum concentration of Dyphylline can be increased when it is combined with Polyestradiol phosphate.
PrazepamThe therapeutic efficacy of Prazepam can be decreased when used in combination with Dyphylline.
PrimidoneThe serum concentration of Dyphylline can be decreased when it is combined with Primidone.
PrinomastatThe serum concentration of Dyphylline can be decreased when it is combined with Prinomastat.
ProbenecidThe serum concentration of Dyphylline can be increased when it is combined with Probenecid.
PropafenoneThe serum concentration of Dyphylline can be increased when it is combined with Propafenone.
PropranololPropranolol may decrease the bronchodilatory activities of Dyphylline.
PropylthiouracilThe serum concentration of Dyphylline can be increased when it is combined with Propylthiouracil.
QuinaprilThe serum concentration of Dyphylline can be decreased when it is combined with Quinapril.
QuinestrolThe serum concentration of Dyphylline can be increased when it is combined with Quinestrol.
QuinineThe serum concentration of Dyphylline can be increased when it is combined with Quinine.
RamiprilThe serum concentration of Dyphylline can be decreased when it is combined with Ramipril.
RemikirenThe serum concentration of Dyphylline can be decreased when it is combined with Remikiren.
RiociguatDyphylline may increase the hypotensive activities of Riociguat.
RitonavirThe serum concentration of Dyphylline can be decreased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Dyphylline can be decreased when it is combined with Rivaroxaban.
SaquinavirThe serum concentration of Dyphylline can be decreased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Dyphylline can be decreased when it is combined with Saxagliptin.
SecobarbitalThe serum concentration of Dyphylline can be decreased when it is combined with Secobarbital.
SimeprevirThe serum concentration of Dyphylline can be decreased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Dyphylline can be decreased when it is combined with Sitagliptin.
SotalolSotalol may decrease the bronchodilatory activities of Dyphylline.
SpiraprilThe serum concentration of Dyphylline can be decreased when it is combined with Spirapril.
Synthetic Conjugated Estrogens, AThe serum concentration of Dyphylline can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Dyphylline can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TelaprevirThe serum concentration of Dyphylline can be decreased when it is combined with Telaprevir.
TemazepamThe therapeutic efficacy of Temazepam can be decreased when used in combination with Dyphylline.
TemocaprilThe serum concentration of Dyphylline can be decreased when it is combined with Temocapril.
ThiabendazoleThe metabolism of Dyphylline can be decreased when combined with Thiabendazole.
ThiamylalThe serum concentration of Dyphylline can be decreased when it is combined with Thiamylal.
ThiopentalThe serum concentration of Dyphylline can be decreased when it is combined with Thiopental.
ThiorphanThe serum concentration of Dyphylline can be decreased when it is combined with Thiorphan.
Thyroid, porcineThe metabolism of Dyphylline can be increased when combined with Thyroid, porcine.
TiboloneThe serum concentration of Dyphylline can be increased when it is combined with Tibolone.
TiclopidineThe metabolism of Dyphylline can be decreased when combined with Ticlopidine.
TimololTimolol may decrease the bronchodilatory activities of Dyphylline.
TipranavirThe serum concentration of Dyphylline can be decreased when it is combined with Tipranavir.
TrandolaprilThe serum concentration of Dyphylline can be decreased when it is combined with Trandolapril.
TriazolamThe therapeutic efficacy of Triazolam can be decreased when used in combination with Dyphylline.
UbenimexThe serum concentration of Dyphylline can be decreased when it is combined with Ubenimex.
VildagliptinThe serum concentration of Dyphylline can be decreased when it is combined with Vildagliptin.
XimelagatranThe serum concentration of Dyphylline can be decreased when it is combined with Ximelagatran.
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Dyphylline.
ZeranolThe serum concentration of Dyphylline can be increased when it is combined with Zeranol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.
Gene Name:
PDE4B
Uniprot ID:
Q07343
Molecular Weight:
83342.695 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Iancu L, Shneur A, Cohen H: Trials with xanthine derivatives in systemic treatment of psoriasis. Dermatologica. 1979;159(1):55-61. [PubMed:225216 ]
  4. Hariton C: Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. [PubMed:7925603 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name:
PDE4A
Uniprot ID:
P27815
Molecular Weight:
98142.155 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  4. Iancu L, Shneur A, Cohen H: Trials with xanthine derivatives in systemic treatment of psoriasis. Dermatologica. 1979;159(1):55-61. [PubMed:225216 ]
  5. Hariton C: Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. [PubMed:7925603 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name:
PDE4C
Uniprot ID:
Q08493
Molecular Weight:
79900.795 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Iancu L, Shneur A, Cohen H: Trials with xanthine derivatives in systemic treatment of psoriasis. Dermatologica. 1979;159(1):55-61. [PubMed:225216 ]
  4. Hariton C: Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. [PubMed:7925603 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin protein ligase binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name:
PDE4D
Uniprot ID:
Q08499
Molecular Weight:
91114.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Hariton C: Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. [PubMed:7925603 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Purine nucleoside binding
Specific Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
ADORA1
Uniprot ID:
P30542
Molecular Weight:
36511.325 Da
References
  1. Schwabe U, Ukena D, Lohse MJ: Xanthine derivatives as antagonists at A1 and A2 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):212-21. [PubMed:2997628 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Identical protein binding
Specific Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
ADORA2A
Uniprot ID:
P29274
Molecular Weight:
44706.925 Da
References
  1. Schwabe U, Ukena D, Lohse MJ: Xanthine derivatives as antagonists at A1 and A2 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):212-21. [PubMed:2997628 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May have a role in muscle signal transduction.
Gene Name:
PDE7A
Uniprot ID:
Q13946
Molecular Weight:
55504.475 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in the control of cAMP-mediated neural activity and cAMP metabolism in the brain.
Gene Name:
PDE7B
Uniprot ID:
Q9NP56
Molecular Weight:
51834.855 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23